Utah Cash Conversion Cycle vs Free Cash Flow Per Share Analysis
| UTMD Stock | USD 65.29 0.72 1.12% |
Utah Medical financial indicator trend analysis is much more than just breaking down Utah Medical Products prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Utah Medical Products is a good investment. Please check the relationship between Utah Medical Cash Conversion Cycle and its Free Cash Flow Per Share accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Utah Medical Products. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Cash Conversion Cycle vs Free Cash Flow Per Share
Cash Conversion Cycle vs Free Cash Flow Per Share Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Utah Medical Products Cash Conversion Cycle account and Free Cash Flow Per Share. At this time, the significance of the direction appears to have very week relationship.
The correlation between Utah Medical's Cash Conversion Cycle and Free Cash Flow Per Share is 0.25. Overlapping area represents the amount of variation of Cash Conversion Cycle that can explain the historical movement of Free Cash Flow Per Share in the same time period over historical financial statements of Utah Medical Products, assuming nothing else is changed. The correlation between historical values of Utah Medical's Cash Conversion Cycle and Free Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Conversion Cycle of Utah Medical Products are associated (or correlated) with its Free Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Per Share has no effect on the direction of Cash Conversion Cycle i.e., Utah Medical's Cash Conversion Cycle and Free Cash Flow Per Share go up and down completely randomly.
Correlation Coefficient | 0.25 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Cash Conversion Cycle
Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Most indicators from Utah Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Utah Medical Products current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Utah Medical Products. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. The current year's Enterprise Value is expected to grow to about 202 M, whereas Selling General Administrative is forecasted to decline to about 6.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 30.9M | 32.2M | 30.0M | 20.6M | Total Revenue | 49.1M | 52.3M | 50.2M | 36.6M |
Utah Medical fundamental ratios Correlations
Click cells to compare fundamentals
Utah Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Utah Medical fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 109.8M | 111.7M | 115.6M | 123.9M | 135.5M | 142.2M | |
| Other Current Liab | 2.4M | 2.9M | 2.7M | 4.3M | 3.3M | 2.6M | |
| Total Current Liabilities | 3.4M | 3.8M | 3.6M | 5.8M | 4.7M | 4.6M | |
| Total Stockholder Equity | 101.1M | 102.8M | 107.1M | 114.3M | 128.3M | 134.7M | |
| Property Plant And Equipment Net | 10.7M | 11.3M | 11.0M | 10.6M | 10.6M | 9.6M | |
| Net Debt | (42.4M) | (51.3M) | (60.6M) | (74.7M) | (92.6M) | (87.9M) | |
| Retained Earnings | 110.8M | 111.0M | 115.3M | 126.0M | 138.3M | 145.3M | |
| Cash | 42.8M | 51.6M | 61.0M | 75.1M | 92.9M | 97.5M | |
| Non Current Assets Total | 54.9M | 49.5M | 42.4M | 34.0M | 29.2M | 27.1M | |
| Non Currrent Assets Other | 54.9M | (49.5M) | (2.1M) | (1.5M) | (1.0) | (0.95) | |
| Cash And Short Term Investments | 42.8M | 51.6M | 61.0M | 75.1M | 92.9M | 97.5M | |
| Net Receivables | 4.7M | 4.1M | 5.1M | 5.5M | 3.4M | 4.5M | |
| Common Stock Shares Outstanding | 3.7M | 3.7M | 3.7M | 3.6M | 3.6M | 5.0M | |
| Liabilities And Stockholders Equity | 109.8M | 111.7M | 115.6M | 123.9M | 135.5M | 142.2M | |
| Non Current Liabilities Total | 5.2M | 5.1M | 4.8M | 3.9M | 2.4M | 2.3M | |
| Inventory | 6.9M | 6.2M | 6.6M | 8.8M | 9.6M | 10.1M | |
| Other Current Assets | 443K | 346K | 456K | 515K | 481K | 457.0K | |
| Other Stockholder Equity | 17K | 115K | 841K | 251K | 594.0K | 564.3K | |
| Total Liab | 8.7M | 8.9M | 8.4M | 9.6M | 7.1M | 9.7M | |
| Property Plant And Equipment Gross | 10.7M | 11.3M | 33.9M | 33.2M | 34.3M | 36.0M | |
| Total Current Assets | 54.9M | 62.3M | 73.2M | 89.9M | 106.3M | 111.6M | |
| Accumulated Other Comprehensive Income | (9.8M) | (8.3M) | (9.1M) | (12.0M) | (10.7M) | (10.1M) | |
| Intangible Assets | 30.2M | 24.0M | 17.3M | 10.4M | 4.9M | 4.7M | |
| Accounts Payable | 1.1M | 788K | 761K | 1.2M | 769K | 1.3M | |
| Property Plant Equipment | 10.7M | 11.3M | 11.0M | 10.2M | 11.8M | 10.1M | |
| Good Will | 14.0M | 14.2M | 14.1M | 13.4M | 13.7M | 13.0M | |
| Other Liab | 4.9M | 4.8M | 4.5M | 3.3M | 3.8M | 4.9M | |
| Net Tangible Assets | 56.9M | 64.7M | 75.7M | 90.5M | 104.1M | 62.4M | |
| Retained Earnings Total Equity | 110.8M | 111.0M | 115.3M | 126.0M | 144.9M | 93.3M | |
| Capital Surpluse | 18K | 115K | 841K | 251K | 225.9K | 214.6K | |
| Deferred Long Term Liab | 521K | 651K | 577K | 549K | 494.1K | 356.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Utah Medical Products is a strong investment it is important to analyze Utah Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Utah Medical's future performance. For an informed investment choice regarding Utah Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Utah Medical Products. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Utah Medical. If investors know Utah will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Utah Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Dividend Share 1.2 | Earnings Share 4.28 | Revenue Per Share 12.392 | Quarterly Revenue Growth (0.20) |
The market value of Utah Medical Products is measured differently than its book value, which is the value of Utah that is recorded on the company's balance sheet. Investors also form their own opinion of Utah Medical's value that differs from its market value or its book value, called intrinsic value, which is Utah Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Utah Medical's market value can be influenced by many factors that don't directly affect Utah Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Utah Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Utah Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Utah Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.